Cancer

Title
The study of radiation therapy plus the drug cetuximab versus radiation therapy plus the drug cisplatin for the treatment of HPV-associated oropharynx cancer.
Trial Number
203776081711
Number of Participants
706
Principal Investigator

Bahman Emami

M.D., FACR, FASTRO
Radiation Oncology
Professor
Eligibility

Participants must be 18 years or older and have a pathologically proven diagnosis of squamous cell carcinoma, which is HPV positive. Participants must have exams by a radiation and a medical oncologist as well as an ENT or head and neck surgeon, which must include a laryngopharyngoscopy. Other required tests include: CBC,CMP, swallowing evaluation, audiogram, EKG, CT/MRI/PET of neck, a whole-body PET/CT, a dental evaluation, and a possible feeding tube evaluation.

Purpose

The purpose of this study is to compare the effects, good and/or bad, of two standard treatments for head and neck cancer: radiation therapy and cisplatin or radiation therapy and cetuximab. The two treatments may be comparable in treating your cancer, but radiation and cetuximab may result in less severe side effects.

Enrollment

(708) 216-2568

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.